131 related articles for article (PubMed ID: 9167766)
21. Recombinant human erythropoietin β: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients.
Durmaz O; Demirkaya M; Sevinir B
Pediatr Hematol Oncol; 2011 Sep; 28(6):461-8. PubMed ID: 21707225
[TBL] [Abstract][Full Text] [Related]
22. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO.
Mittman N; Sreedhara R; Mushnick R; Chattopadhyay J; Zelmanovic D; Vaseghi M; Avram MM
Am J Kidney Dis; 1997 Dec; 30(6):912-22. PubMed ID: 9398141
[TBL] [Abstract][Full Text] [Related]
23. Serum erythropoietin and creatinine concentrations as predictive factors for response to recombinant human erythropoietin treatment in anaemic tumour patients on chemotherapy.
Fjornes T; Wiedemann GJ; Sack K; Jelkmann W
Oncol Rep; 1998; 5(1):81-6. PubMed ID: 9458299
[TBL] [Abstract][Full Text] [Related]
24. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo.
Cascinu S; Fedeli A; Del Ferro E; Luzi Fedeli S; Catalano G
J Clin Oncol; 1994 May; 12(5):1058-62. PubMed ID: 8164030
[TBL] [Abstract][Full Text] [Related]
25. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
[TBL] [Abstract][Full Text] [Related]
26. Circulating transferrin receptor during erythropoietin medication of anemic patients with rheumatoid arthritis.
Pettersson T; Teppo AM; Siimes MA
Scand J Rheumatol; 1996; 25(5):321-4. PubMed ID: 8921926
[TBL] [Abstract][Full Text] [Related]
27. High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study.
Stebler C; Tichelli A; Dazzi H; Gratwohl A; Nissen C; Speck B
Exp Hematol; 1990 Dec; 18(11):1204-8. PubMed ID: 2226680
[TBL] [Abstract][Full Text] [Related]
28. [The role of human recombinant erythropoietin in oncologic surgery].
Mercuriali F
Tumori; 1997; 83(4 Suppl 2):S16-9. PubMed ID: 9487379
[TBL] [Abstract][Full Text] [Related]
29. The effects of recombinant human erythropoietin on autologous blood donation in rheumatoid arthritis patients with anaemia.
Matsui H; Shiraishi N; Yasuda T; Nezuka T
Clin Exp Rheumatol; 1999; 17(1):69-74. PubMed ID: 10084035
[TBL] [Abstract][Full Text] [Related]
30. Comparison of plasma erythropoietin concentrations and iron status in hemodialyzed patients not requiring and requiring rHuEpo therapy.
Majdan M; Ksiazek A; Kozioł M; Spasiewicz D; Swatowski A; Solski J
Nephron; 1996; 73(3):425-9. PubMed ID: 8832602
[TBL] [Abstract][Full Text] [Related]
31. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
[TBL] [Abstract][Full Text] [Related]
32. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
Chen YC; Hung SC; Tarng DC
Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
[TBL] [Abstract][Full Text] [Related]
33. High doses of recombinant human erythropoietin fail to accelerate platelet reconstitution in allogeneic bone marrow transplantation. Results of a pilot study.
Vannucchi AM; Bosi A; Linari S; Guidi S; Longo G; Lombardini L; Mariani MP; Saccardi R; Laszlo D; Rossi Ferrini P
Haematologica; 1997; 82(1):53-6. PubMed ID: 9107083
[TBL] [Abstract][Full Text] [Related]
34. Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin.
Beguin Y; Clemons GK; Pootrakul P; Fillet G
Blood; 1993 Feb; 81(4):1067-76. PubMed ID: 8427988
[TBL] [Abstract][Full Text] [Related]
35. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors.
Ludwig H; Fritz E; Leitgeb C; Krainer M; Kührer I; Sagaster P; Umek H
Ann Oncol; 1993 Feb; 4(2):161-7. PubMed ID: 8448084
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer--a randomized study.
Johansson JE; Wersäll P; Brandberg Y; Andersson SO; Nordström L;
Scand J Urol Nephrol; 2001 Sep; 35(4):288-94. PubMed ID: 11676354
[TBL] [Abstract][Full Text] [Related]
37. Variations in erythropoiesis and serum ferritin during erythropoietin therapy for anaemia of end-stage renal disease.
Barosi G; Merlo C; Palestra P; Liberato NL; Guarnone R; Di Dio F; Piazza V; Salvadeo A
Acta Haematol; 1993; 90(1):13-8. PubMed ID: 8237268
[TBL] [Abstract][Full Text] [Related]
38. Erythropoietin production in patients with malignant lymphoma.
Kostova G; Siljanovski N
Prilozi; 2005 Dec; 26(2):157-68. PubMed ID: 16400237
[TBL] [Abstract][Full Text] [Related]
39. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy.
Case DC; Bukowski RM; Carey RW; Fishkin EH; Henry DH; Jacobson RJ; Jones SE; Keller AM; Kugler JW; Nichols CR
J Natl Cancer Inst; 1993 May; 85(10):801-6. PubMed ID: 8487324
[TBL] [Abstract][Full Text] [Related]
40. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration.
Oster W; Herrmann F; Gamm H; Zeile G; Lindemann A; Müller G; Brune T; Kraemer HP; Mertelsmann R
J Clin Oncol; 1990 Jun; 8(6):956-62. PubMed ID: 2189957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
